Semaphorin 4D contributes to rheumatoid arthritis by inducing inflammatory cytokine production: Pathogenic and therapeutic implications

Arthritis and Rheumatology

Volumn 67, Issue 6, 2015, Pages 1481-1490

  Yoshida, Yuji ^a   Ogata, Atsushi ^a   Kang, Sujin ^a   Ebina, Kousuke ^a   Shi, Kenrin ^a,b   Nojima, Satoshi ^a   Kimura, Tetsuya ^a   Ito, Daisuke ^a   Morimoto, Keiko ^a   Nishide, Masayuki ^a   Hosokawa, Takashi ^a   Hirano, Toru ^a   Shima, Yoshihito ^a   Narazaki, Masashi ^a   Tsuboi, Hideki ^c   Saeki, Yukihiko ^c   Tomita, Tetsuya ^a   Tanaka, Toshio ^a   Kumanogoh, Atsushi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

^c MINAMI OSAKA GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE 1; ALKALINE PHOSPHATASE BONE ISOENZYME; C REACTIVE PROTEIN; CD14 ANTIGEN; CD3 ANTIGEN; CYTOKINE; INTERLEUKIN 6; OSTEOCALCIN; SEMAPHORIN; SEMAPHORIN 4D; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADAM PROTEIN; AGGRECANASE-1; AUTACOID; CD100 ANTIGEN; IL6 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MESSENGER RNA; PROCOLLAGEN N PROTEINASE;

ARTHRITIS; ARTICLE; BONE TURNOVER; CELL SURFACE; CLINICAL FEATURE; CYTOKINE PRODUCTION; DAS28; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID LEVEL; SYNOVIOCYTE; SYNOVIUM; ADULT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CELL LINE; CHEMISTRY; CYTOLOGY; EXPERIMENTAL ARTHRITIS; FEMALE; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNOVIAL FLUID; VERY ELDERLY; YOUNG ADULT;

ADAM PROTEINS; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL LINE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MICE; MIDDLE AGED; MONOCYTES; PROCOLLAGEN N-ENDOPEPTIDASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEMAPHORINS; SYNOVIAL FLUID; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84929864374     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39086     Document Type: Article

References (50)

1. Kochi Y, Suzuki A, Yamamoto K., Genetic basis of rheumatoid arthritis: a current review. Biochem Biophys Res Commun 2014; 452: 254-62.
2. Holmdahl R, Malmstrom V, Burkhardt H., Autoimmune priming, tissue attack and chronic inflammation: the three stages of rheumatoid arthritis. Eur J Immunol 2014; 44: 1593-9.
3. Ogura H, Murakami M, Okuyama Y, Tsuruoka M, Kitabayashi C, Kanamoto M, et al., Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008; 29: 628-36.
4. Zhao W, Zhang C, Shi M, Zhang J, Li M, Xue X, et al., The discoidin domain receptor 2/annexin A2/matrix metalloproteinase 13 loop promotes joint destruction in arthritis through promoting migration and invasion of fibroblast-like synoviocytes. Arthritis Rheumatol 2014; 66: 2355-67.
5. Cessak G, Kuzawinska O, Burda A, Lis K, Wojnar M, Mirowska-Guzel D, et al., TNF inhibitors: mechanisms of action, approved and off-label indications. Pharmacol Rep 2014; 66: 836-44.
6. Yoshida Y, Tanaka T., Interleukin 6 and rheumatoid arthritis. Biomed Res Int 2014; 2014: 698313.
7. Kolodkin AL., Semaphorins: mediators of repulsive growth cone guidance. Trends Cell Biol 1996; 6: 15-22.
8. Zhou Y, Gunput RA, Pasterkamp RJ., Semaphorin signaling: progress made and promises ahead. Trends Biochem Sci 2008; 33: 161-70.
9. Takamatsu H, Kumanogoh A., Diverse roles for semaphorin-plexin signaling in the immune system. Trends Immunol 2012; 33: 127-35.
10. Kumanogoh A, Kikutani H., Immunological functions of the neuropilins and plexins as receptors for semaphorins. Nat Rev Immunol 2013; 13: 802-14.
11. Vadasz Z, Attias D, Kessel A, Toubi E., Neuropilins and semaphorins: from angiogenesis to autoimmunity. Autoimmun Rev 2010; 9: 825-9.
12. Gu C, Giraudo E., The role of semaphorins and their receptors in vascular development and cancer. Exp Cell Res 2013; 319: 1306-16.
13. Rehman M, Tamagnone L., Semaphorins in cancer: biological mechanisms and therapeutic approaches. Semin Cell Dev Biol 2013; 24: 179-89.
14. Rizzolio S, Tamagnone L., Semaphorin signals on the road to cancer invasion and metastasis. Cell Adh Migr 2007; 1: 62-8.
15. Negishi-Koga T, Shinohara M, Komatsu N, Bito H, Kodama T, Friedel RH, et al., Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 2011; 17: 1473-80.
16. Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H., Osteoprotection by semaphorin 3A. Nature 2012; 485: 69-74.
17. Fukuda T, Takeda S, Xu R, Ochi H, Sunamura S, Sato T, et al., Sema3A regulates bone-mass accrual through sensory innervations. Nature 2013; 497: 490-3.
18. Kumanogoh A, Kikutani H., Immune semaphorins: a new area of semaphorin research. J Cell Sci 2003; 116: 3463-70.
19. Nakatsuji Y, Okuno T, Moriya M, Sugimoto T, Kinoshita M, Takamatsu H, et al., Elevation of Sema4A implicates Th cell skewing and the efficacy of IFN-β therapy in multiple sclerosis. J Immunol 2012; 188: 4858-65.
20. Xie G, Roshandel D, Sherva R, Monach PA, Lu EY, Kung T, et al., Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1∗04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum 2013; 65: 2457-68.
21. Catalano A., The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis. J Immunol 2010; 185: 6373-83.
22. Gras C, Eiz-Vesper B, Jaimes Y, Immenschuh S, Jacobs R, Witte T, et al., Secreted semaphorin 5A activates immune effector cells and is a biomarker for rheumatoid arthritis. Arthritis Rheumatol 2014; 66: 1461-71.
23. Vadasz Z, Haj T, Halasz K, Rosner I, Slobodin G, Attias D, et al., Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus. Arthritis Res Ther 2012; 14: R146.
24. Bougeret C, Mansur IG, Dastot H, Schmid M, Mahouy G, Bensussan A, et al., Increased surface expression of a newly identified 150-kDa dimer early after human T lymphocyte activation. J Immunol 1992; 148: 318-23.
25. Elhabazi A, Marie-Cardine A, Chabbert-de Ponnat I, Bensussan A, Boumsell L., Structure and function of the immune semaphorin CD100/SEMA4D. Crit Rev Immunol 2003; 23: 65-81.
26. Zhang Y, Liu B, Ma Y, Jin B., Sema 4D/CD100-plexin B is a multifunctional counter-receptor. Cell Mol Immunol 2013; 10: 97-8.
27. Elhabazi A, Delaire S, Bensussan A, Boumsell L, Bismuth G., Biological activity of soluble CD100. I. The extracellular region of CD100 is released from the surface of T lymphocytes by regulated proteolysis. J Immunol 2001; 166: 4341-7.
28. Wang X, Kumanogoh A, Watanabe C, Shi W, Yoshida K, Kikutani H., Functional soluble CD100/Sema4D released from activated lymphocytes: possible role in normal and pathologic immune responses. Blood 2001; 97: 3498-504.
29. Ji JD, Ivashkiv LB., Roles of semaphorins in the immune and hematopoietic system. Rheumatol Int 2009; 29: 727-34.
30. Kumanogoh A, Watanabe C, Lee I, Wang X, Shi W, Araki H, et al., Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity 2000; 13: 621-31.
31. Shi W, Kumanogoh A, Watanabe C, Uchida J, Wang X, Yasui T, et al., The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice. Immunity 2000; 13: 633-42.
32. Ishida I, Kumanogoh A, Suzuki K, Akahani S, Noda K, Kikutani H., Involvement of CD100, a lymphocyte semaphorin, in the activation of the human immune system via CD72: implications for the regulation of immune and inflammatory responses. Int Immunol 2003; 15: 1027-34.
33. Okuno T, Nakatsuji Y, Moriya M, Takamatsu H, Nojima S, Takegahara N, et al., Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 2010; 184: 1499-506.
34. Sierra JR, Corso S, Caione L, Cepero V, Conrotto P, Cignetti A, et al., Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med 2008; 205: 1673-85.
35. Semerano L, Clavel G, Assier E, Denys A, Boissier MC., Blood vessels, a potential therapeutic target in rheumatoid arthritis? Joint Bone Spine 2011; 78: 118-23.
36. Okamoto K, Takayanagi H., Regulation of bone by the adaptive immune system in arthritis. Arthritis Res Ther 2011; 13: 219.
37. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
38. Williams-Skipp C, Raman T, Valuck RJ, Watkins H, Palmer BE, Scheinman RI., Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model. Arthritis Rheum 2009; 60: 408-18.
39. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
40. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL., Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
41. Nagase H, Kashiwagi M., Aggrecanases and cartilage matrix degradation. Arthritis Res Ther 2003; 5: 94-103.
42. Tian Y, Yuan W, Fujita N, Wang J, Wang H, Shapiro IM, et al., Inflammatory cytokines associated with degenerative disc disease control aggrecanase-1 (ADAMTS-4) expression in nucleus pulposus cells through MAPK and NF-κB. Am J Pathol 2013; 182: 2310-21.
43. Yeh ET., CRP as a mediator of disease. Circulation 2004; 109: II11-4.
44. Zhu L, Bergmeier W, Wu J, Jiang H, Stalker TJ, Cieslak M, et al., Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc Natl Acad Sci U S A 2007; 104: 1621-6.
45. Mou P, Zeng Z, Li Q, Liu X, Xin X, Wannemacher KM, et al., Identification of a calmodulin-binding domain in Sema4D that regulates its exodomain shedding in platelets. Blood 2013; 121: 4221-30.
46. Lin EA, Liu CJ., The role of ADAMTSs in arthritis. Protein Cell 2010; 1: 33-47.
47. Edwards DR, Handsley MM, Pennington CJ., The ADAM metalloproteinases. Mol Aspects Med 2008; 29: 258-89.
48. Burrage PS, Mix KS, Brinckerhoff CE., Matrix metalloproteinases: role in arthritis. Front Biosci 2006; 11: 529-43.
49. Kumanogh A, Kikutani H., The CD100-CD72 interaction: a novel mechanism of immune regulation. Trends Immunol 2001; 22: 670-6.
50. Patnaik A, Ramanathan RK, Rasco DW, Weiss GJ, Campello-Iddison V, Eddington C, et al., Phase 1 study of VX15/2503, a humanized IgG4 anti-SEMA4D antibody, in advanced cancer patients [abstract]. J Clin Oncol 2014; 32 Suppl: 5s.